Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Visa Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B), while Visa Inc trades at $375 (market cap $698.56B). The key difference: Visa Inc is far larger — about 12× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Visa Inc for 115 Days on average.
| TAK | V | |
|---|---|---|
Market Cap | $58.16B | $698.56B |
Volume | 2,467,530 | 4,446,146 |
Sector | Health | Financials |
52-Week High | $19.05 | $384.14 |
52-Week Low | $13.23 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $86.04B | $709.14B |
Dividend Yield | 3.36% | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $375.10, up 1.2% today, with a bullish technical outlook and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $40 billion and net income of $20.06 billion, supported by high profitability margins. Recent earnings beats and a consensus analyst price target of $422.24 reflect positive sentiment, while news highlights AI integration and stablecoin partnerships as growth catalysts.
The outlook for Visa remains favorable, driven by earnings momentum and strategic initiatives in digital payments. Key risks include competitive pressures from fintech and regulatory scrutiny, but institutional ownership trends and a dominant market position underpin long-term potential. The stock offers upside based on analyst targets, though investors should monitor execution on AI and payment innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
